Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
HighField Files INDs for Two ADCplex Liposomes with Novel Payloads
Details : HF158K1 is an investigational HER2-targeted immunoliposome therapy designed to deliver the chemotherapy drug doxorubicin to HER2-expressing tumor cells.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 21, 2025
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HFK1 (HF158K1) is a drug encapsulated immunoliposome containing doxorubicin which is under phase 1 clinical development for the treatment of solid tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 18, 2023
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HF158K1, a drug encapsulated immunoliposome containing doxorubicin, which being investigated forbsolid tumors include breast, bladder, pancreatic, ovarian, stomach, colon, prostate, lung, uterus and cervix cancers with HER2 low and HER2+ expression.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 13, 2023
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HF158K1 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 17, 2023
Reset All
